In his presentation yesterday (Saturday, Oct. 3) at the Fall Clinical Dermatology Conference, Brian Berman, M.D., Ph.D., updated the audience on “PDT: What’s New and What’s Important.”
Dr. Berman discussed how to optimize photodynamic therapy (PDT) in the treatment of actinic keratoses (AK). He said several “What’s New” factors will help dermatologists accomplish that optimization.
READ: The next stage in the evolution of PDT
Dr. Berman says today’s PDT is characterized by several new trends:
Shorter aminolevulinic acid (ALA) incubation time
Broad area “field” treatment
Occlusion of ALA for arm and leg AKs
Increased skin temperature during ALA incubation to increase protoporphrin IX (PpIX) and, thus, increase efficacy
Appropriate level of cooling during light exposure and/or very short incubation with ALA to reduce pain during light
Of these, he says, the “What’s Important”—or most
important—advancements are two-fold: “Increased efficacy with occlusion of extremity AKs, and ‘painless’ PDT.”
Dr. Berman is co-director of Skin & Cancer Associates, Aventura, Fla., and also serves as voluntary professor of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine.